地產分類指數續升逾3% 潤地漲8%逼近高位 長實及領展分別越百天及牛熊線
環球新冠疫苗研發露曙光,輝瑞與德國藥廠BioNTech研發新冠肺炎疫苗於人體試驗中有效預防率超過九成遠勝預期。此外,內地10月百強房企首十個月銷售額均值逼近千億人民幣,按年增長12.3%至994.9億人民幣。市場資金繼續由新經濟股轉移至舊經濟股,地產分類指數連續第二天急升,午後高見34,878,現造34,728,續升3.3%。
10隻成份股除昨天飆升14%九倉置業(01997.HK)反覆高見40.25元創逾八個月高無以為繼回吐2.2%報38.4元外,全部續漲1.7%-7.7%。上月總合同銷售額按年升3.5%至260.4億人民幣潤地(01109.HK)升幅最大,股價五連升兼突破9月所創近期高位38.45元,最高見39.15元,暫受制1月初所創紀錄高位40.45元,現造39.1元,續漲7.9%,成交增至1,494萬股。
獲聯席主席楊惠妍於上月29日至本月5日連續6天共增持1.16億股的碧桂園(02007.HK)三連漲,最高見11.44元創逾九個月高,現造11.26元,續升1.8%。中國海外(00688.HK)高見21.7元,暫受制百天線(22.2元),現造21.5元,續升3.1%。
新地(00016.HK)及長實集團(01113.HK)分別升破牛熊線及百天線(104.5元及41.8元),最高見107.5元及42.55元,現造106.9元及42.4元,續升2.8%及3.9%;恆地(00012.HK)及新世界(00017.HK)續升2%及3%,分別高見31.5元及41元,創逾4個月及2個月高。
獲麥格理升價71.2元的領展(00823.HK)重越牛熊線(69.4元),最高見70元,現造69.5元,續升3%。恆隆地產(00101.HK)高見21.35元,創逾兩個月高,現造21.15,續升1.7%。
另外,非地產分類成份股太古A(00019.HK)更續漲9%報44.4元,創逾四個月高,表現為最強藍籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.